We have located links that may give you full text access.
Impact of extranodal extension on risk stratification in papillary thyroid carcinoma.
BACKGROUND: The current American Thyroid Association (ATA) risk stratification system for papillary thyroid carcinoma (PTC) incorporates the number and size of positive lymph nodes (LNs), but places less weight on extranodal extension (ENE). We investigated how to incorporate ENE into the current system to predict recurrence better in PTC N1 patients.
METHODS: A total of 369 N1 PTC patients without distant metastasis were enrolled. We identified the combination of number of positive LNs and LNs with ENE that had the highest C-index in multivariable Cox proportional hazard models. ENE number was incorporated into the current system considering the recurrence rate and unadjusted and adjusted hazard ratios of subgroups. Kaplan-Meier curves for recurrence based on current and alternative systems were compared by log-rank test.
RESULTS: Recurrence rate for the subgroup with ≤5 positive LNs and 1-3 ENEs (7/61, 11.5%) was higher than that of the subgroup with ≤5 positive LNs without ENE [(5/129, 3.9%), adjusted HR 3.42 (0.99-11.75), P =0.050]. In contrast, adjusted HRs of the subgroup with >5 positive LNs and 1-3 ENEs [2.33 (0.52-10.35)] or with ≥4 ENEs [3.86 (1.05-14.17)] were not higher than those of subgroup with >5 LNs without ENE [4.47 (1.16-17.19)]. Incorporating ENE into the current system as an intermediate risk group yielded a lower log-rank P-value (0.05 vs. 0.01) than current system.
CONCLUSIONS: The presence of ENE in low volume LN metastasis confers an intermediate risk of recurrence. Incorporating ENE into the current system allows more accurate decisions regarding further management of PTC N1 patients. .
METHODS: A total of 369 N1 PTC patients without distant metastasis were enrolled. We identified the combination of number of positive LNs and LNs with ENE that had the highest C-index in multivariable Cox proportional hazard models. ENE number was incorporated into the current system considering the recurrence rate and unadjusted and adjusted hazard ratios of subgroups. Kaplan-Meier curves for recurrence based on current and alternative systems were compared by log-rank test.
RESULTS: Recurrence rate for the subgroup with ≤5 positive LNs and 1-3 ENEs (7/61, 11.5%) was higher than that of the subgroup with ≤5 positive LNs without ENE [(5/129, 3.9%), adjusted HR 3.42 (0.99-11.75), P =0.050]. In contrast, adjusted HRs of the subgroup with >5 positive LNs and 1-3 ENEs [2.33 (0.52-10.35)] or with ≥4 ENEs [3.86 (1.05-14.17)] were not higher than those of subgroup with >5 LNs without ENE [4.47 (1.16-17.19)]. Incorporating ENE into the current system as an intermediate risk group yielded a lower log-rank P-value (0.05 vs. 0.01) than current system.
CONCLUSIONS: The presence of ENE in low volume LN metastasis confers an intermediate risk of recurrence. Incorporating ENE into the current system allows more accurate decisions regarding further management of PTC N1 patients. .
Full text links
Related Resources
Trending Papers
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Anti-Arrhythmic Effects of Heart Failure Guideline-Directed Medical Therapy and Their Role in the Prevention of Sudden Cardiac Death: From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond.Journal of Clinical Medicine 2024 Februrary 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app